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The cardiorenal syndrome is a clinical and pathophysiological entity defined as the concomitant presence of renal and
cardiovascular dysfunction. In patients with severe sepsis and septic shock, acute cardiovascular, and renal derangements are
common, that is, the septic cardiorenal syndrome. The aim of this paper is to describe the pathophysiology and clinical features of
septic cardiorenal syndrome in light of the actual clinical and experimental evidence. In particular, the importance of systemic and
intrarenal endothelial dysfunction, alterations of kidney perfusion, and myocardial function, organ “crosstalk” and ubiquitous
inflammatory injury have been extensively reviewed in light of their role in cardiorenal syndrome etiology. Treatment includes
early and targeted optimization of hemodynamics to reverse systemic hypotension and restore urinary output. In case of persistent
renal impairment, renal replacement therapy may be used to remove cytokines and restore renal function.
1. Introduction and Definitions
The cardiorenal syndromes (CRSs) are relatively new clinical
and pathophysiological entities which have been defined
as the concomitant presence of renal and cardiovascular
dysfunction [1]. According to Ronco and colleagues, five
subtypes of the syndrome exist [2]. Type 1 CRS is defined
as acute renal failure secondary to an abrupt worsening of
cardiac function, for example, cardiogenic shock or acute
congestive heart failure. Type 2 CRS describes a progressive
and permanent chronic kidney dysfunction which is caused
by chronic worsening in cardiac function, for example,
chronic congestive heart failure. Type 3 CRS consists of an
acute cardiac dysfunction (e.g., heart failure, arrhythmia,
and ischemia) secondary to an abrupt worsening of renal
function (e.g., acute kidney ischemia or glomerulonephritis).
Type 4 CRS describes a state of chronic kidney disease
(e.g., chronic glomerular disease) causing a decreased cardiac
function, cardiac hypertrophy, and/or increased risk of
adverse cardiovascular events. Type 5 CRS reflects con-
comitant cardiac and renal dysfunctions in the setting of a
systemic condition which primarily affect both organs (e.g.,
diabetes mellitus and sepsis) [2].
The simultaneous presence of acute cardiovascular and
renal alterations in septic patients is defined as septic car-
diorenal syndrome. Cardiac and renal dysfunctions are often
part of the clinical picture of severe sepsis and septic shock
[3]. Following classification of Ronco, sepsis may represent
an acute cause of Type 5 cardiorenal syndrome [2].
Renal dysfunction can be observed during severe sepsis
and is part of the clinical picture of septic shock and multiple
organ failure [1]. Acute renal failure is defined as an acute
worsening of renal function based on increasing levels of
serum creatinine or reduced urinary output [4]. Following
RIFLE criteria, acute kidney injury (AKI) ranges from
minor alterations in renal function to indication for renal
replacement therapy [5]. AKI is common among critically ill
patients, and sepsis and septic shock account for more than
50% of cases [6–8]. As suggested by Bellomo et al., sepsis-
induced inflammatory injury of microvessels, hypotension
and hypoperfusion during septic shock may play a causative
role on development of AKI [2].
Moreover, a high proportion of septic patients develop
left ventricular systolic impairment, either with or without
involvement of other organs [9]. Cardiac dysfunction in
sepsis is characterized by decreased contractility, impaired
ventricular response to fluid therapy, and, in some patients,
progressive ventricular dilatation. Current data support a
complex underlying pathophysiology with a host of potential
pathways leading to myocardial depression [10]. This is
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Figure 1: Hemodynamic alteration in underresuscitated sepsis patients (see text for details).
a well-described but poorly understood phenomenon in
which microvascular alterations, autonomic dysregulation,
metabolic changes and inflammatory signalling have all
previously been hypothesized as potential mechanism for
cardiac dysfunction [11].
Despite several studies investigate the incidence of AKI in
sepsis or pathophysiology of septic cardiomyopathy, data are
lacking about concomitant renal and cardiac injury in severe
sepsis or septic shock. The purpose of this paper is to review
pathophysiology and clinical aspects of septic cardiorenal
syndrome in light of the actual clinical and experimental
evidence.
2. Epidemiology
Incidence of sepsis in Europe is 350 new cases on 100.000
inhabitants per year [12] and its prevalence is high among all
hospitalised patients (one–third) and, mostly, among those
admitted to ICUs. Indeed, 10%–15% of all patients admitted
to ICUs develop septic shock [13].
Moreover, numerous studies have shown septic AKI to be
highly common among the critically ill, ranging from 16%
to 41% [14, 15] of patients with severe sepsis and septic
shock [16]. Patients with septic AKI are often older, have a
higher prevalence of comorbidity and are more severely ill
than those with nonseptic AKI [17].
On the other side, myocardial dysfunction may occur
in up to 20% of patients with septic shock. Patients with
myocardial dysfunction have significantly higher mortality
(70%) compared to septic patients without cardiovascular
impairment (20%) [18]. Biomarkers such as cardiac tro-
ponin T and I have been studied in sepsis. Elevations in
cardiac troponin T and I correlate with the presence of
left ventricular systolic dysfunction [19–21] and 30–80% of
patients with severe sepsis and septic shock show NSTEMI
on ECG with serum troponin values above the normal
range. Furthermore, levels of cardiac troponin also correlate
with duration of hypotension and intensity of vasopressor
support in patients with septic shock [22, 23]. The potential
role of B-type natriuretic peptide (BNP) as a biomarker
has also been evaluated in septic patients. Recent studies
have shown increased levels of BNP in patients with severe
sepsis and septic shock [24]. Levels of BNP correlate with
the degree of myocardial dysfunction and mortality [10].
More recently, echocardiography has been utilized to define
heart dysfunction in severe sepsis and septic shock. In a
longitudinal study with transthoracic echocardiography in
septic shock patients, left ventricular ejection fraction was
significantly depressed in all patients [25], resulting in severe
reductions in left ventricular stroke volume. Of interest, these
abnormalities were more pronounced in survivors than in
nonsurvivors.
3. Hemodynamic Alterations
Type 1 cardiorenal syndrome is defined as an acute cardiac
dysfunction which leads to acute renal failure, that is, acute
cardiorenal syndrome [1]. Traditionally, septic AKI has been
seen as the consequence of renal hypoperfusion and reduced
renal blood flow, that is, an ischemic kidney injury, which
occurs during severe sepsis, septic shock or multiple organ
failure [26]. During early phases of septic shock, and in
underresuscitated patients, systemic vasodilation and fluid
shift reduce cardiac preload, thus reducing cardiac output.
This may decrease renal blood flow (RBF) [27] and reduce
glomerular filtration rate, leading to prerenal azotemia [26].
If renal hypoperfusion continues, ischemic injury to kidneys
occurs, and AKI develops (see Figure 1).
Sepsis and septic shock are also characterized by a
variable degree of myocardial dysfunction, which is linked to
multiple factors. Experimental studies on laboratory animals
show the role of mediators such as cytokines, endothelin
[28], and nitric oxide [29] on myocardial cells and mitochon-
drial dysfunction [30] as possible mechanisms involved in
this phenomenon [10]. Moreover, ventilation with positive
end-expiratory pressure required by patients with severe
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Figure 2: Hemodynamic alteration in fluid-resuscitated sepsis
patients (see text for details).
sepsis or septic shock may contribute to intrarenal hemo-
dynamic alterations. In a prospective experimental study on
humans, Jacob et al. [31] evaluated the effects of increasing
intrathoracic pressure with positive end-expiratory pressure
on renal blood flow. High values of PEEP were associated to
decreased mean arterial pressures, cardiac output and uri-
nary output. PEEP-induced decrease in urinary output was
correlated to renal perfusion pressure decrease. Furthermore,
as demonstrated by Peng et al. [32] in bacteremic dogs, the
presence of intrabdominal hypertension can adversely affect
cardiac output and contribute to renal hypoperfusion (see
Figure 1).
As a consequence of all these alterations, renal blood flow,
and oxygen delivery decrease [33]. There is evidence that
early goal directed hemodynamic optimization has positive
effects on survival of septic patients, and restoring and
maintaining good organ perfusion and oxygenation may
account for this effect [34]. To preserve or restore renal func-
tion, a judicious, targeted use of fluids and vasopressors is
recommended [35]. Recovery of renal function and diuresis
herald a general improvement in systemic oxygen delivery
and consumption which is of good prognostic value [26].
4. Microvascular Alterations
Sepsis-induced alterations of microcirculation are ubiq-
uitous and are linked to both cardiovascular and renal
failure [36]. Several studies [37–39] suggest that systemic
vasodilation leads to reduced tissue oxygen delivery (DO2),
with progressive mitochondrial dysfunction/disruption and
cytopathic hypoxia, which can cause organ failure [40].
In early phases of severe sepsis/septic shock, reduction in
renal blood flow is associated to arterial hypotension, fluid
shift, hypovolemia, and low cardiac output, that is, ischemic
AKI (see above). Old experimental studies showed that
renal blood flow was reduced in endotoxemic rats [41].
However, in fluid-resuscitated septic patients with AKI,
cardiac output is normal or high and glomerular filtration
rate can be low despite normal or high renal blood flow
[26] (see Figure 2). This is because glomerular filtration rate
is related to glomerular filtration pressure, which relies on
the balance between afferent and efferent arteriolar tone.
During sepsis glomerular efferent arteriola dilates more
than afferent, thus reducing glomerular filtration pressure
[42] (see Figure 2). Vasopressors, such norepinephrine,
are employed to treat arterial hypotension during septic
shock [3]. Besides increasing renal blood flow through a
restored renal perfusion pressure, norepinephrine increases
glomerular filtration rate acting on the afferent-efferent
arteriolar tone, with a more intense vasoconstrictive effect
on efferent arteriola [43]. In experimental models of septic
shock in ewes, Langenberg at al. suggest that recovery from
AKI has been associated to an increase in renal vascular
resistance [44]. While a judicious use of vasopressors may
contribute to restore glomerular filtration pressure and
renal function, overzealous use of norepinephrine may also
lead to afferent arteriolar vasoconstriction which reduces
glomerular blood flow and filtration pressure. Moreover, the
increased circulating level of catecholamines, which is part
of the neurohormonal stress response to sepsis, results in
sustained angiotensin II release, which can adversely affect
renal perfusion [45]. All these effects contribute to cause and
maintain renal dysfunction.
5. Organ “Crosstalk”
Type 3 cardiorenal syndrome is defined as AKI leading
to acute cardiac dysfunction, that is, acute renocardiac
syndrome [1]. Indeed, a marked left ventricular dilata-
tion has been shown in experimental models of bilateral
renal ischemia in mouse [46]. Three mechanisms may be
involved, that is, fluid overload, myocardial inflammation,
and reduced cytokines clearance.
During sepsis, renal hypoperfusion brings to progressive
worsening fluid accumulation which can adversely impact on
myocardial function, further decreasing cardiac output and
renal blood flow, and initiating a vicious cycle between renal
and cardiovascular dysfunction. Cardiac filling pressures
increase, as does myocardial work load and oxygen consump-
tion [27]. Sympathetic burden on cardiovascular system can
be already high due to neurohormonal response to stress
and use of vasopressors. Thus, acute cardiac dysfunction can
precipitate, with further reduction in renal blood flow (see
Figure 3).
The ischemic injury to kidneys may contribute to “long
distance” organ damage in sepsis [47]. During ischemic renal
injury in mouse, Kelly demonstrated increased myocardial
levels of mRNA for TNF-alpha, IL-1, and ICAM-1, resulting
in increased leukocyte infiltration and activation [46]. The
same inflammatory damage could occur during sepsis-
induced ischemic renal injury and lead to myocardial cells
apoptosis and fibrosis [46], with progressive myocardial dys-
function. Indeed, sepsis-associated myocardial dysfunction
can be prevented by anti-TNF-alpha antibodies or receptor
antagonists [46] and cytokines removal by the mean of
high volume hemofiltration has shown beneficial effects on
cardiac function and hemodynamics in septic patients [48].
Knotek et al. showed the effect of TNF neutralization on renal
function by a TNF-soluble receptor in the endotoxemic mice,
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Figure 3: Organ “crosstalk” (see text for details).
demonstrating the role of TNF in the early renal dysfunction
(16 h) [49].
Finally, AKI itself can result in reduced clearance of
systemic, circulating cytokines, which can worsen myocardial
inflammatory injury. Expressions of cytokines and leukocyte
adhesion molecules, and expression of membrane ion and
water-channel protein in distant organs, including the car-
diovascular systems, are altered during AKI [50].
6. Organ Inflammation
Type 5 cardiorenal syndrome is defined as a systemic insult
which leads to concomitant renal and cardiac dysfunction
[1]. An inflammatory pathogenesis can be a common key
feature for both the kidneys and cardiovascular system
during sepsis, leading to cell ultrastructural alterations and
organ dysfunction [47, 51]. In a prospective observational
study on 1836 hospitalized patients with community-
acquired pneumonia, Murugan at al. demonstrated that
renal injury and AKI associated to pneumonia recognize
an inflammatory pathogenesis [52]. In this paper, outcome
of renal injured patients was strictly related to IL-6 plasma
concentration [52]. Endotoxin mediated release of TNF-α
may affect simultaneously kidneys and cardiovascular system
[53]. In the endotoxemic mice, Knotek et al. suggested that
TNF-alpha can be also released by glomerular mesangial cells
in response to Gram-negative endotoxin and act promoting
leukocyte migration and activation in renal tissue, thus
inducing septic AKI [49]. In an experimental model of
cultured human proximal tubular cells, Jo et al. demon-
strated that endotoxin, TNF-α and other pro-inflammatory
cytokines induced apoptosis of renal tubular cells [54].
Inflammation has a well-defined role in inducing hypo-
tension in septic patients [55]. Proinflammatory cytokines,
such as TNF-α, IL-1 and IL-6, may also induce myocardial
inhibition [28–30]. Sepsis-induced release of nitric oxide and
increased production of peroxynitrite also depress myocar-
dial function. Tavernier et al. studied contractile function
of cardiac myocytes isolated 12 h after induction of endo-
toxemia in rats. Authors demonstrated that cardiomyocytes
from LPS-injected rats had depressed twitch shortening
compared with control cells and that contractile depression
was unaffected by inhibitors of nitric oxide synthase [56].
Moreover, in a retrospective analysis of human autoptic
specimens, Kooy et al. demonstrated the formation of per-
oxynitrite within the myocardium during sepsis, suggesting a
role for peroxynitrite in inflammation-associated myocardial
dysfunction [57]. On the other hand, renal hypoperfusion
during sepsis-induced low cardiac output state leads to
myocardial inflammation, apoptosis, and fibrosis (see above)
[46].
7. Changes in Microvascular Permeability
Sepsis induced inflammatory response causes diffuse alter-
ation in microcirculation [58]. Microcirculatory dysfunction
contributes to altered tissue perfusion and oxygen deliv-
ery/consumption, thus contributing to septic shock and
renal failure, that is, type 5 CRS [2]. Enhanced endothelial
expression of leukocyte adhesion molecules and alteration of
endothelial cells contacts can increase microvascular perme-
ability, thus leading to extravascular fluid shift, fluid over-
load, hypovolemia, reduced venous return, and low cardiac
output. Interstitial edema further reduces oxygen delivery to
tissues, and fluid overload is an independent risk factor for
mortality among septic patients with AKI [59]. At renal level,
increased expression of adhesion molecules is associated to
enhanced leukocytes migration, which may lead to endothe-
lial cells injury and detachment, as shown by Paller during
experimental renal ischemic injury in rats [60]. Altered
glomerular permeability results in microalbuminuria [61].
Glycocalix is a thin (0.5–1.2 μm) molecular structure
which lies beneath capillary endothelial cells and regulates
capillary flow, leukocytes adhesion and migration, platelets
adhesion and coagulation [62]. It is important in regulating
capillary permeability. Several studies suggest that glycocalix
disruption may contribute to increased permeability, both
in systemic and renal microcirculation [63, 64], increasing
leukostasis, microthrombosis, fluid shift, and interstitial
edema. This leads to reduced oxygen delivery to tissues and
organ failure [65].
8. Clinical Features
Septic cardiorenal syndrome is a clinical diagnosis. Its defi-
nition implies concomitant presence of acute hemodynamic
and renal dysfunction in a patient with sepsis. Sepsis is
defined by two or more signs among tachycardia, tachyp-
nea, leukocitosis/leukopenia, and fever/hypothermia [3]. In
severe sepsis one acute organ dysfunction is present, usually
cardiovascular or renal. Arterial hypotension, an arterial sys-
tolic pressure below 95 mmHg, or 40 mmHg below the usual
in previously hypertensive patients, is typically observed
when hemodynamic dysfunction becomes manifest [3].
Myocardial dysfunction may be present as well, with reduced
myocardial contractility and left ventricular ejection fraction
[66]. Serum cardiac troponins and B-type natriuretic peptide
may be elevated as they are sensitive and specific biomarkers
of myocardial damage [67]. As suggested by Ammann et al.,
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in septic, critically ill patients, serum troponin I levels
may increase in absence of coronary artery disease, as a
marker of myocardial dysfunction, and its levels correlate
with mortality rates [68, 69]. However, when AKI is present,
serum troponin may be elevated due to underlying renal
dysfunction [70], as demonstrated by Musso and Colleagues
in patients with chronic renal failure [71].
Typically, reduced urine output and increased serum
creatinine are considered as clinical signs of acute renal
failure in clinical practice [72], and they were included
in RIFLE criteria [6, 7]. However, serum creatinine lacks
of sensitivity since its plasma levels rise only after half of
the renal function is lost [73]. Alternative biomarkers for
AKI include serum interleukin-18 and urinary kidney injury
molecule-1, cystatin-C, and beta-2 microglobulin [74]. In
an observational cohort study, Soni et al. demonstrated that
neutrophil gelatinase associated lipocallin (NGAL) acted as
a sensitive biomarker for AKI, particularly for septic AKI
[72]. In a series of 143 critically ill children, serum NGAL
was a sensitive marker for AKI during systemic inflammatory
response syndrome (SIRS) and septic shock [75]. Its plasma
level correlated with severity of the syndrome and showed
some specificity for septic shock [75]. Recently, Bagshaw
et al., in a prospective observational study, demonstrated
that patients with septic AKI had higher levels of plasma
and urine NGAL compared to those with nonseptic AKI
[76]. Interestingly, NGAL, with interleukin-1 receptor antag-
onist and protein C, was recently included among plasma
biomarkers which could allow an early diagnosis of septic
shock and multiple organ failure in patients admitted to
emergency department with suspected sepsis [77].
9. Treatment
Removal of infective source, antibiotic therapy and support-
ive care are all indicated in presence of sepsis-associated car-
diovascular and renal dysfunction [3]. Early hemodynamic
optimization was efficacious in reducing mortality among
critically ill septic patients [34]. Fluids are administered to
restore intravenous volume and vasopressors or inotropic
drugs are infused to revert systemic vasodilation and myocar-
dial depression. Their use should be targeted to specific and
clinical end points, such as mean arterial pressure or central
venous oxygen saturation [78]. Increased venous return
and increased myocardial contractility lead to increased
cardiac output. This may contribute to improved renal blood
perfusion and glomerular filtration, thus restoring urinary
output [79]. Loop diuretics, such furosemide, are often used
to increase and/or maintain urinary output during septic
AKI, but their efficacy has been questioned and their use
may be detrimental on renal function [76]. If oliguria is
present, fluid administration should be judicious as volume
overload and tissue edema may develop, contributing to
impaired lung function and tissue oxygenation [79]. Once
systemic cardiovascular optimization has been obtained, a
shift towards more restrictive fluid administration strategies
has been advocated to reduce AKI associated complications
[76]. When renal function is persistently reduced despite
hemodynamic optimization, continuous renal replacement
therapy (CRRT) is indicated [80]. Worsening serum cre-
atinine levels, volume overload, metabolic acidosis, and
electrolytic alterations usually mandate CRRT. CRRT, and
particularly high volume venovenous hemofiltration, may
also modulate inflammatory response during sepsis, acting
through cytokine removal or adsorption, even though the
exact mechanism is still debated [81]. However, definite
evidence of CRRT for nonrenal indications is still lacking,
venovenous hemofiltration can improve hemodynamics and
revert sepsis-associated hypotension [82]. Thus, in patients
with septic cardiorenal syndrome, CRRT may not be only
supportive, but also contribute to reverse common causative
factors.
10. Conclusions
Cardiorenal syndrome is common among patients with
severe sepsis and septic shock. Pathogenesis is related to mul-
tiple factors affecting both the heart and kidneys, including
shock related renal hypoperfusion, systemic and intrarenal
vasodilation, ubiquitous inflammatory injury to tissues,
endothelial dysfunction, and altered capillary permeability.
Injured kidneys can further impair myocardial function, thus
contributing to maintain shock and organ hypoperfusion.
Early and targeted optimization of hemodynamics is indi-
cated to reverse systemic hypotension and to restore urinary
output. In case of persistent renal impairment, venovenous
hemofiltration may be used to remove cytokines and restore
renal function.
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